BioNTech SE Enters Global Co-Development Deal

TL;DR

BNTX inks global co-development deal, details TBD.

AI Summary

On June 2, 2025, BioNTech SE entered into a Global Co-Development and Commercialization Agreement with an unnamed partner. This agreement outlines the terms for co-developing and commercializing a specific product, though the details of the product and the partner are not disclosed in this filing.

Why It Matters

This agreement signifies BioNTech's strategic expansion into new co-development opportunities, potentially broadening its product pipeline and market reach.

Risk Assessment

Risk Level: medium — The lack of specific details regarding the partner and the product in the filing introduces uncertainty about the potential success and financial implications of the agreement.

Key Players & Entities

• BioNTech SE (company) — Registrant and party to the agreement
• June 2, 2025 (date) — Date the agreement was entered into

FAQ

From the Filing

0001776985-25-000057.txt : 20250908 0001776985-25-000057.hdr.sgml : 20250908 20250908070153 ACCESSION NUMBER: 0001776985-25-000057 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250908 FILED AS OF DATE: 20250908 DATE AS OF CHANGE: 20250908 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 251298528 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kbmsagreement8sep2025.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF SEPTEMBER 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On June 2, 2025, BioNTech SE (Nasdaq: BNTX, “ BioNTech ”, “ we ” or “ us ”) entered into a Global Co-Development and Co-Commercialization Agreement (the “ Original Agreement ”) with Bristol-Myers Squibb Company (“ BMS ”) to jointly develop, manufacture and commercialize our investigational bispecific antibody BNT327 across numerous solid tumor types. We assigned our rights and obligations under the Original Agreement to BioNTech US Inc., pursuant to an Assignment and Assumption Agreement dated June 2, 2025 which was amended on August 15, 2025. In connection with the assignment, the parties also entered into a Parent Guarantee in favor of BMS dated June 2, 2025. The Original Agreement was amended and restated on August 15, 2025 to further define the performance-related rights and obligations of the collaboration (as so amended and restated, the “ BMS Agreement ”). As previously disclosed, under the BMS Agreement, BMS will pay us $1.5 billion in an upfront payment and $2 billion total in non-contingent anniversary payments through 2028. In addition, we will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones. The parties will equally share global profits and losses. The parties have agreed to use commercially reasonable efforts to jointly develop BNT327, as a monotherapy or in combination with other products, pursuant to a joint development plan (the “ JDP ”). Development costs will generally be shared equally&#59; provided, if a particular joint clinical trial involves BNT327 in combination with a proprietary or in-licensed asset of either party, cost sharing will be on an adjusted basis, subject to certain exceptions. Each party may propose new clinical trials for additional indications or combinations to the JDP. If the other party declines co-funding of a proposed new trial in the JDP, the proposing party may proceed independently at its own cost, under the oversight of the joint development committee, subject to certain reimbursement rights against the other party. The partie